Thermo Fisher Scientific

Dr. Tim Sandle's SmartNote series discusses how a risk-based approach to environmental monitoring helps facilities maintain control over their environment and supports quality assurance efforts. Plus, they highlight the importance of selecting appropriate monitoring locations and taking proactive measures based on monitoring results to ensure consistent environmental quality and mitigate potential risks to product safety and integrity. 

Learn about the typical state-of-the-art setup for high-throughput peptide mapping using chromatography and mass spectrometry (MS) techniques, as well as ways of simplifying mapping data.

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research.

Experience flexibility with TaqMan assays, offering over 2.8 million predesigned options to meet your specific needs.

An intelligent, on-premise platform connecting all the steps of your post-discovery routine qPCR workflows into one single ecosystem. Contact sales for a demo

Innovative qPCR tools for your bioanalysis and quality control. Fast-track your bioanalysis & QC with scalable innovative qPCR tools.

TaqMan SNP Genotyping Assays help you detect and distinguish single-nucleotide polymorphisms (SNPs) accurately and efficiently.

Multiplex better with the newest additions to the TaqMan portfolio

This note demonstrates identification of Infliximab charge variants from intact mass analysis enabled by two-dimensional liquid chromatography

Cell culture media is a foundational component of any biotherapeutic manufacturing workflow, crucial for maintaining cellular health and viability, maximizing titers, and supporting high product quality. As such, building a biotherapeutic manufacturing process with an optimized basal medium and feed system is vital to achieving optimal results and accelerating the speed-to-market of your product. However, the process of finding the most suitable basal medium and supplementation strategy can be challenging, as it requires balancing many key cell culture process variables to achieve specific technical goals within budget and time constraints. This guide will provide an insight into each development stage and offer best practices to help you achieve your project goals on time and within budget.

Webinar Date/Time: Wednesday, August 9, 2023 at 5pm CEST | 11am EDT | 8am PDT

This customer note demonstrates the implementation of native SEC-MS using the Vanquish Duo UHPLC system.

With advances in the technologies used in LC-MS-based proteomics workflows, sensitive, reproducible, and efficient single-cell proteomics is now possible. Learn about these advances and how they work in concert to maximize the combination of protein and peptide identifications and sample throughput.

Webinar Dates/Times: Thursday, June 29, 2023 at 17:00 CEST | 11:00 EDT | 08:00 PDT

This customer note will demonstrate the suitability of SEC for a fast and reproducible evaluation of adeno-associated virus (AAV) product titers

Discover how the Ramina Process Analyzer integrates with the 500L HyPerforma DynaDrive bioreactor to perform accurate in-line measurements and prediction models.

Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products. This piece highlights new technologies and strategies to reduce risk and execute consistently.

Fri, Oct 21, 2022 11:00 AM EDT Learn how Karl Mechtler has developed an end-to-end workflow to efficiently prepare and analyze samples for single-cell proteomics by mass spectrometry. This workflow enables direct injection of single cells to identify approximately 1,500 protein groups per analytical run and uncover the surprising heterogeneity of cell populations.

Thursday, September 29, 2022 at 7am PT | 10am ET | 4pm CET Novel methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio using charge detection mass spectrometry on the Q Exactive UHMR mass spectrometer with Direct Mass Technology mode.

Wednesday, September 28, 2022 at 10 AM EST | 4 PM CET Optimize your late-phase strategy to prepare your biologic for commercialization. CDMO experts share their time-tested best practices on how to adapt for uncertain market demand to get your drug to market on time.

When it comes to biotech, both the academic and industry settings are crucial in developing novel medicines. Dr Brent Cezairliyan has experienced both sides of biotech, first through an academic career exploring bacterial pathogenesis, and now in his administrative role at Octagon Therapeutics. The company, headquartered in Cambridge, Massachusetts, focuses on autoimmune disease treatments. By developing targeted approaches to the inflammatory nature of the immune system, they hope their advances in biotech help future scientists navigate the field for years to come.

The 5’ capping is a CQA for mRNA vaccines and therapeutics, and needs to be fully characterized. Learn a sensitive, robust LC-HRAM-MS/MS method for identification and quantitation of 5’ cap.

Thursday, June 30, 2022 at 11am PST | 1pm CST | 2pm EST As CRISPR based gene editing progresses from research to therapeutic applications, there is a growing need for high quality GMP grade materials, including the Cas9 protein and supporting instruments, and to minimize off target events. This webinar will discuss the development process of a GMP-manufactured Cas9 protein along with causes of off target events and how to minimize risk with high fidelity Cas9 protein.

To gain a better appreciation for saliva and its growing use within the diagnostics research market, we’ll take a closer look at some foundational questions about saliva’s composition, physiological function, and its underappreciated history in the medical field.

After being diagnosed with Hodgkins lymphoma at age 15, Dr Joshua Schiffman was driven to pursue a career in medicine, starting as a pediatric oncologist, and was later drawn to the biotech side of the industry. Dr Schiffman was fascinated with a tidbit of knowledge: elephants almost never get cancer. He met Dr Avi Schroeder at a conference in Israel, and the two wondered how they could take this research about elephants’ cancer-fighting genes and apply it to humans. Together, they co-founded PEEL Therapeutics, the organization’s name meaning elephant in Hebrew, and currently work to bring together nature, medicine, and technology for the betterment of humankind. In this episode, Dr Schiffman provides a hopeful outlook on how nature and biotech can lead scientists to harness the power of evolution and create a bright future for medicine.

While still considering himself a fundamental basic scientist, Samir Ounzain is embracing the biotech industry trend of merging academic research and biotechnological drug development. In this episode, Ounzain talks about his path from a dark theater as a kid watching Jurassic Park to the lab studying the dark matter of the human genome – and eventually to the founding of Haya Therapeutics, a biotech startup aiming to discover and develop safe and effective, tissue- and cell-selective, genome-based therapies for fibrotic diseases.